ES2090325T3 - Inhibicion de rechazo de aloinjertos y xenoinjertos concordantes. - Google Patents

Inhibicion de rechazo de aloinjertos y xenoinjertos concordantes.

Info

Publication number
ES2090325T3
ES2090325T3 ES91907303T ES91907303T ES2090325T3 ES 2090325 T3 ES2090325 T3 ES 2090325T3 ES 91907303 T ES91907303 T ES 91907303T ES 91907303 T ES91907303 T ES 91907303T ES 2090325 T3 ES2090325 T3 ES 2090325T3
Authority
ES
Spain
Prior art keywords
rejection
xenointerges
conjunctional
allocation
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91907303T
Other languages
English (en)
Inventor
David James Graham White
Den Bogaerde Johan Beyers Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imutran Ltd
Original Assignee
Imutran Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imutran Ltd filed Critical Imutran Ltd
Application granted granted Critical
Publication of ES2090325T3 publication Critical patent/ES2090325T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE PUEDEN UTILIZAR LA CICLOSPORINA A, U OTRO COMPUESTO QUE TENGA ACTIVIDAD COMO LA DE LA CICLOSPORINA A, Y EL FACTOR VENENO DE COBRA, U OTRO INHIBIDOR COMPLEMENTARIO, JUNTOS PARA PROMOVER LA SUPERVIVENCIA DE LOS ALLOINJERTOS Y LOS XENOINJERTOS CONCORDANTES Y PARA EVITAR EL RECHAZO A DICHOS INJERTOS.
ES91907303T 1990-04-09 1991-04-04 Inhibicion de rechazo de aloinjertos y xenoinjertos concordantes. Expired - Lifetime ES2090325T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909007971A GB9007971D0 (en) 1990-04-09 1990-04-09 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
ES2090325T3 true ES2090325T3 (es) 1996-10-16

Family

ID=10674123

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91907303T Expired - Lifetime ES2090325T3 (es) 1990-04-09 1991-04-04 Inhibicion de rechazo de aloinjertos y xenoinjertos concordantes.

Country Status (22)

Country Link
EP (1) EP0527762B1 (es)
JP (1) JP3518547B2 (es)
CN (1) CN1040178C (es)
AT (1) ATE141167T1 (es)
AU (1) AU7555591A (es)
CZ (1) CZ283119B6 (es)
DE (1) DE69121401T2 (es)
DK (1) DK0527762T3 (es)
ES (1) ES2090325T3 (es)
GB (1) GB9007971D0 (es)
GR (1) GR3021642T3 (es)
HK (1) HK48597A (es)
IE (1) IE911153A1 (es)
IL (1) IL97788A (es)
IN (1) IN173149B (es)
MY (1) MY106158A (es)
NZ (1) NZ237739A (es)
PT (1) PT97277B (es)
SG (1) SG47465A1 (es)
SK (1) SK279949B6 (es)
WO (1) WO1991015221A1 (es)
ZA (1) ZA912467B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60020727T2 (de) 1999-10-27 2006-05-04 Robert London Zhong Zusammensetzung zur vorbeugung und behandlung von transplantatabstossung
AU2001291579B2 (en) * 2000-09-29 2006-08-31 Viron Therapeutics Inc. Use of serp- 1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
EP2338511A3 (en) * 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
EP2073898A1 (en) 2006-10-10 2009-07-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Complement inhibition for improved nerve regeneration
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
SI3011345T1 (sl) 2013-08-07 2017-12-29 Alexion Pharmaceuticals, Inc. Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)

Also Published As

Publication number Publication date
CN1056240A (zh) 1991-11-20
HK48597A (en) 1997-04-25
PT97277B (pt) 1998-08-31
WO1991015221A1 (en) 1991-10-17
DE69121401D1 (de) 1996-09-19
CS9100988A2 (en) 1991-12-17
DK0527762T3 (da) 1996-09-02
PT97277A (pt) 1992-01-31
AU7555591A (en) 1991-10-30
SK279949B6 (sk) 1999-06-11
IL97788A (en) 1998-02-08
DE69121401T2 (de) 1996-12-12
CZ283119B6 (cs) 1998-01-14
NZ237739A (en) 1993-09-27
ZA912467B (en) 1992-12-30
GB9007971D0 (en) 1990-06-06
IL97788A0 (en) 1992-06-21
JPH05507266A (ja) 1993-10-21
MY106158A (en) 1995-03-31
GR3021642T3 (en) 1997-02-28
IE911153A1 (en) 1991-10-09
SG47465A1 (en) 1998-04-17
EP0527762A1 (en) 1993-02-24
IN173149B (es) 1994-02-19
CN1040178C (zh) 1998-10-14
JP3518547B2 (ja) 2004-04-12
ATE141167T1 (de) 1996-08-15
EP0527762B1 (en) 1996-08-14

Similar Documents

Publication Publication Date Title
ES2099158T3 (es) Tratamiento del rechazo de trasplantes o de enfermedades autoinmunitarias y complejo de la formula general x-pro-y-boropro asociada al mismo.
ES2178036T3 (es) Derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que le contienen.
ES2085299T3 (es) Uso de rapamicina y sus derivados y profarmacos en la fabricacion de un medicamento para inhibir el rechazo de los transplantes en los mamiferos.
BG100474A (bg) О-арил, о-алкил, о-алкенил и о-алкинил-макролидис имуносупресивно действие
EP0163475A3 (en) Immunoregulation
TR199901410T2 (xx) Yeni bir bile�im bi�imi.
ATE185548T1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
CO4700485A1 (es) Anticuerpos anti-icam-1 modificados y su uso en el tratamiento de inflamaciones
ES2191292T3 (es) Compuestos antivirales poliaromaticos.
NO953372D0 (no) Anvendelse av lamotrigin ved behandling av neuro-AIDS
EP0484071A3 (en) Synergism of hiv reverse transcriptase inhibitors
ES2090325T3 (es) Inhibicion de rechazo de aloinjertos y xenoinjertos concordantes.
NO20035434D0 (no) Behandling eller profylakse av transplantasjonsavst degree tning av insulinproduserende celler
ES2055415T3 (es) S-adenosil-metionina para el tratamiento de pancreatitis y del inmunorechazo del trasplante de pancreas.
EP0618600A3 (en) Electrolytic solution for electrolytic capacitor and its application in an electrolytic capacitor.
IT1273751B (it) Derivati azaciclici
NO2019032I1 (no) Treosulfan
PT1223971E (pt) Composicoes e metodos para prevencao e tratamento da rejeicao de transplante
ES2053942T3 (es) Empleo de aductos de oxido de 1,2-butileno en compuestos organicos h-azidas como lubricantes y lubricantes que contienen estos aductos.
DE69109539D1 (de) Verminderung und Inhibition des Gehalts von Äthylenthioharnstoff in Alkylenbisdithiocarbamaten.
DE69124252D1 (de) Oberflächen-abriebbehandlung für kleine gegenstände
FR2712322B1 (fr) Cloison amovible et ses éléments constitutifs.
FI952018A7 (fi) BHAP-yhdisteiden käyttö yhdessä muiden ei-nukleosidi-käänteistransskri ptaasi-inhibiittoreiden kanssa HIV-infektion hoitoon
ATE225172T1 (de) Acylurea-verbindungen zur behandlung von coccidioidomycosis bei warmblütigen tieren
TH13234A (th) การยับยั้งปฏิกิริยาที่ไม่ยอมรับเนื้อเยื่อที่ปลูกของส่วนปลูกตอนต่อของสมาชิกพันธุ์เดียวกัน และส่วนปลูกตอนต่อของพันธุ์ที่แตกต่างกัน แต่กลมกลืนกัน

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 527762

Country of ref document: ES

FG2A Definitive protection

Ref document number: 527762

Country of ref document: ES